Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Democrats vow to protect Speaker Mike Johnson from being ousted from office
WASHINGTON (AP) — House Democrats will vote to save Republican Speaker Mike Johnson’s job should som2024-05-01Xi Stresses Rural Revitalization in Inspections to Shaanxi, Henan
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01- Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01
Xi Stresses Implementing Guiding Principles of Key Party Congress in Armed Forces
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01- CLEVELAND (AP) — The Cleveland Browns got Greg Newsome II covered.As expected, the team picked up th2024-05-01
Xi Meets German Chancellor Olaf Scholz
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01
atest comment